Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model

Buruli ulcer (BU) is a skin disease caused by Mycobacterium ulcerans infection that requires long-term antibiotic treatment and/or surgical excision. In this study, we investigated the therapeutic efficacy of the rifamycin derivative, rifalazil (RLZ) (also known as KRM-1648), in an advanced M. ulcer...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukano, Hanako, Nakanaga, Kazue, Goto, Masamichi, Yoshida, Mitsunori, Ishii, Norihisa, Hoshino, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536621/
https://www.ncbi.nlm.nih.gov/pubmed/36201529
http://dx.doi.org/10.1371/journal.pone.0274742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536621/
https://www.ncbi.nlm.nih.gov/pubmed/36201529
http://dx.doi.org/10.1371/journal.pone.0274742

Ejemplares similares